


 Cite this: *Lab Chip*, 2022, 22, 4369

Bioprinting-based automated deposition of single cancer cell spheroids into oxygen sensor microelectrode wells

 Johannes Dornhof, ^{†a} Viktoria Zieger, ^{†b} Jochen Kieninger, ^a Daniel Frejek,^c Roland Zengerle,^{bc} Gerald A. Urban,^a Sabrina Kartmann ^{bc} and Andreas Weltin *^a

Three-dimensional (3D) cell agglomerates, such as microtissues, organoids, and spheroids, become increasingly relevant in biomedicine. They can provide *in vitro* models that recapitulate functions of the original tissue in the body and have applications in cancer research. For example, they are widely used in organ-on-chip systems. Microsensors can provide essential real-time information on cell metabolism as well as the reliability and quality of culture conditions. The combination of sensors and 3D cell cultures, especially single spheroids, is challenging in terms of reproducible formation, manipulation, and access to spheroids, precise positioning near sensors, and high cell-to-volume ratios to obtain meaningful biosignals in the most parallel approach possible. To overcome this challenge, we combined state-of-the-art bioprinting techniques to automatically print tumour spheroids directly into microwells of a chip-based electrochemical oxygen sensor array. We demonstrated highly accurate and reproducible spheroid formation (diameter of approx. 200 μm) and a spheroid deposition precision of 25 μm within a volume of 22 nl per droplet. Microstructures and hydrogel-coated microwells allowed the placement of single MCF-7 breast cancer spheroids close to the sensor electrodes. The microelectrode wells were sealed for oxygen measurements within a 55 nl volume for fast concentration changes. Accurate and stable amperometric oxygen sensor performance was demonstrated from atmospheric to anoxic regions. Cellular respiration rates from single tumour spheroids in the range of 450–850 fmol min^{-1} were determined, and alterations of cell metabolism upon drug exposure were shown. Our results uniquely combine bioprinting with 3D cell culture monitoring and demonstrate the much-needed effort for facilitation, parallelization, sensor integration, and drug delivery in 3D cell culture and organ-on-chip experiments. The workflow has a high degree of automation and potential for scalability. In order to achieve greater flexibility in the automation of spheroid formation and trapping, we employed a method based on drop-on-demand liquid handling systems, instead of the typical on-chip approach commonly used in microfluidics. Its relevance ranges from fundamental metabolic research over standardization of cell culture experiments and toxicological studies, to personalized medicine, e.g. patient-specific chemotherapy.

 Received 29th July 2022,
 Accepted 6th October 2022

DOI: 10.1039/d2lc00705c

rsc.li/loc

1 Introduction

Microtissues, organoids, and spheroids are three dimensional (3D) cell agglomerates that can replicate specific functions of organs or tissues in a cell culture model. They are becoming increasingly attractive both from their vast application perspective in cell biology and biomedicine and regarding the increasing number of microsystems and microfluidic lab-on-

chip devices that utilize them. Microsensors can deliver essential information on cell metabolism and culture conditions continuously and *in situ*. Integrating microsensors, as well as microsystems and microfluidics in general, into 3D cell cultures, presents time- and resource-consuming challenges: general microfluidic handling, reliable cell culturing to generate consistent microtissues, confinement or trapping to isolate and manipulate them, and, in our case, getting them close enough to a sensor in order to obtain meaningful biosignals. Therefore, we introduce a bioprinting approach based on drop-on-demand printing¹ that offers a high degree of automation and flexibility for liquid, drug, and cell handling, in order to print spheroids or any 3D cell culture directly onto a sensor chip and into oxygen microsensor wells.

^a Laboratory for Sensors, IMTEK – Department of Microsystems Engineering, University of Freiburg, Freiburg, Germany. E-mail: weltin@imtek.de

^b Laboratory for MEMS Applications, IMTEK – Department of Microsystems Engineering, University of Freiburg, Freiburg, Germany

^c Hahn-Schickard, Freiburg, Germany

[†] Contributed equally.


Potential therapeutics for the treatment of diseases like cancer are currently mostly tested on animal models or two-dimensional (2D) cell monolayers of the respective cancer type before being tested on humans. However, after successfully passing these preclinical trials, only a minimal portion of them will ever be used to treat a patient² as the majority of candidates have proven ineffective or have adverse effects. The reason for that is an inadequate representation of the actual situation in the affected tissue or organ. Especially in 2D cell cultures, cells lack intercellular interaction and physiological concentration gradients of solute metabolites, signalling molecules, and other growth-determining factors.³ Cells growing into 3D spherical networks, overcome these limitations and begin to gradually replace such traditional models. For cancerous tissue in particular, 3D cell cultures have shown a higher resistance to chemotherapeutic agents and significantly better replication of the *in vivo* situation compared to 2D equivalent.⁴

Scaffold-based spheroids can form spontaneously within matrix-based cultures from single cell-level embedded into an artificial extracellular matrix (ECM). Such an approach leads to a heterogeneous culture with a rather broad size distribution.⁵ Additionally, the choice of ECM hydrogel significantly determines the properties of the culture,⁶ e.g. with regard to the availability of metabolites, and can vary greatly, so that comparability between experiments with different ECMs and their standardization can be insufficient. In addition, there are scaffold-free approaches where several individual cells in suspension typically aggregate and form a compact spherical cell network either in ultra-low attachment plates, hanging droplets, microfluidic devices, rotating bioreactors, microwells, or by magnetic manipulation.⁷ In contrast to conventional ECM-based methods, such a forced formation of spheroids results in a shorter forming time with improved homogeneity and is therefore highly suited for high-throughput evaluations.

Besides the precise formation of spheroids, an accurate assessment of the cell state is essential for a reliable analysis of properties or reactions of the cells. Established methods include optical observation in combination with staining techniques. These can be applied to analyse a variety of different biological markers with a high selectivity and throughput. However, many of the commonly used staining dyes interact with the cells and are only suitable for an end-point analysis making continuous measurements of changes in cell characteristics extremely challenging. By introducing microsensors into the microenvironment of the cells, such changes can be recorded in real-time with a high spatiotemporal resolution.⁸ In particular, respiration rates are key indicator for cell viability and changes in cellular metabolism. Consequently, sensor-based measurements of dissolved molecules involved in the cell metabolism, can be used as indicating parameters for pharmacodynamics of active compounds and metabolic transformations.

Therefore, mostly electrochemical and optical microsensors were integrated into platforms for cultivation of

2D^{9–19} and matrix-based 3D^{17,20–24} cultures. However, most microsystems lack scalability, and more efforts toward high-throughput measurements are required.¹⁶ For more detailed analyses of metabolites and the biochemical microenvironment, the access to single spheroids is desirable, including a high cell to media volume ratio, which is challenging due to the small size of the microtissues. Thus, electrochemical electrodes were integrated into hanging droplet systems for a highly precise measurement of the lactate production²⁵ and glucose consumption^{25,26} of single microtissues. Measuring the oxygen consumption, on the other hand, is highly challenging in such open systems. Bavli *et al.*²⁷ successfully integrated oxygen-sensing microbeads into single spheroids, which is an invasive approach and therefore not ideal in situations where no interaction between measurement element and cells is desired. Optical analysis systems, in which the oxygen content of single spheroid cultures can be measured, e.g. the Seahorse XFe96 Analyzer,²⁸ are based on optical sensors with embedded fluorophores. However, their non-linear transfer function reduces the accuracy at low oxygen concentrations, in contrast to electrochemical sensors.

Other non-invasive approaches to measure the dissolved oxygen concentration in the microenvironment of single spheroids can be categorized into needle-type probes and chip-based devices.²⁹ Needle-type microsensor probes^{30–32} consist of an electrode tip and can be used to measure the local oxygen concentration within a spheroid or at certain distances to its surface to profile the environment and obtain a dependency of concentration and position. Since they require a continuous re-positioning, they are less suitable for simultaneous evaluations of many spheroids in parallel. Chip-based approaches^{33–35} incorporate microsensors into the culture volume, such as microfluidic structures or microwells, and are more suitable to monitor the overall microenvironment in high-throughput.

Controlling the precise positioning of cell aggregates opens new perspectives for the microsensor-based assessment of the sample. Bioprinting has proven to be a powerful technology to control the spatial arrangement of cells in 2D or 3D. Whereas most approaches use bioinks with cell suspension,^{36–39} the printing of 3D cell aggregates, such as spheroids or organoids, is less common and increases the complexity. However, many current problems, such as the use of physiologically relevant 3D *in vitro* models, the handling of patient-derived microtissues or the generation of complex tissue models, show the high need for controlled processing and positioning of 3D cell aggregates.^{1,36,40,41} Recently, Chen, *et al.*⁴⁰ reported a bioprinting approach in which microtissues are precisely deposited in droplets generated using acoustic waves. However, the complexity of the experimental setup and the small reservoir volume limit a robust and standardized automation for large-scale single spheroid deposition. Other approaches rely on pick-and-place, such as the method reported by Heo, *et al.*⁴¹ and Ayan, *et al.*,⁴² which used a glass capillary to lift single spheroids



out of a reservoir with an applied negative pressure. Since the lifting pressure is strongly dependent on the spheroid size and the used medium, and since strong local forces act on the spheroids for a short time, the generalization of the method is difficult. In contrast, drop-on-demand (DoD) methods where the droplets are dispensed *via* a microvalve (spheroOne® Cellenion SASU, France) or by mechanical deformation of an elastic tube¹ have proven to be compatible with a large range of different samples and offer a simplified implementation.

In this work, we have combined for the first time an advanced 3D bioprinting process¹ for deposition of spheroids or arbitrary 3D cell culture models, with a microsensor platform with embedded amperometric oxygen sensor electrodes. Here, breast cancer spheroids were automatically deposited *via* DoD directly into microsensor wells of nanoliter-range volumes, bringing sensor and microtissue in close contact. In this paper, the spheroid formation and deposition using bioprinting techniques are discussed. Electrochemical oxygen sensors allowed the precise and reproducible determination of single spheroid metabolic rates, including changes upon cancer drug exposure. Our approach explores advanced and automated microtissue manipulation together with the integration of sensors in 3D cell culture, towards more efficient and parallelized procedures, *e.g.* in drug screening.

2 Concept: bioprinting of spheroids onto microsensors

For successful access to the oxygen consumption and metabolism of bioprinted single spheroids *via* microsensors,

numerous boundary conditions must be fulfilled: (i) sensor and spheroid must be brought into close proximity to each other in a controlled manner; (ii) remain in that position for hours to ensure a reliable sensor result and (iii) have approximately the same size in the micrometre-range; (iv) the culture volume must be below microlitre-range for single spheroids³⁰ to guarantee a measurable concentration change; (v) the volume in which measurements are taken must be sealable from the external environment to prevent an undesired influx of additional oxygen and (vi) long-term stability of the sensor within the complex measurement electrolyte must be ensured over the whole experiment. At the same time, the platform has to be compatible with the DoD bioprinting process.

The electrochemical sensor platform consists of a glass chip with an array of nine circular (\varnothing 200 μm) platinum microelectrodes on its surface, fabricated on a wafer-level⁹ (Fig. 1b). Dedicated microwells (\varnothing 500 μm) patterned with permanent epoxy-based photoresist confine single spheroids at the electrodes and allow the real-time acquisition of the oxygen concentration directly within their microenvironment for monitoring both, culture conditions and cellular respiration. Breast cancer spheroids are cultured outside the platform and individually printed by DoD directly into the microelectrode wells, using a bioprinting technique¹ developed at the Laboratory for MEMS Applications (Fig. 1a and b). The bioprinting accomplishes the otherwise demanding and time-consuming tasks of trapping and precisely positioning spheroids in small volumes and close to the sensor electrodes. Its high degree of automation allows parallelization and offers flexibility as well as powerful liquid handling options, *e.g.* for drug delivery. Spheroid integrity and viability are maintained without the use of artificial



Fig. 1 Single spheroid deposition set-up and oxygen-sensing microwells. (a) Scheme of the bioprinting process: spheroids, homogeneously distributed in a reservoir, are transferred fully automatically into microwells with embedded oxygen sensors by means of a droplet dispenser. All components are software-controlled. (b) PipeJet® nanodispenser with the protruding capillary nozzle above the sensor glass chip with microwell array and electrode layout. (c) Cross-sectional view of one oxygen sensor well showing all relevant components and materials of the system.



ECM, allowing reproducible measurement of metabolic changes in response to external stimuli over several hours and simple isolation of the microtissues for further analyses.

Oxygen sensor microelectrodes are located at the bottom of the microwells. The electrodes and the entire bottom of the microwell are coated with a poly(2-hydroxyethyl methacrylate) (pHEMA)-based hydrogel membrane, which serves as a diffusion limitation for the oxygen measurement and a spacer between the spheroid and the electrode surface (Fig. 1c). The hydrogel's cell repellent properties prevent cell adhesion and spheroid disintegration. It is important that the concave shape of the hydrogel layer ensures a centred position of the settling spheroid, approximately 25 μm above the microelectrode. A platinum counter electrode and two silver/silver chloride reference electrodes are embedded into the chip surface for electrochemical measurements in a 3-electrode configuration.

To limit the available oxygen during respiration measurements, the microelectrode wells are covered in regular intervals with a glass slide ensuring a small measurement volume around the spheroid of just 55 nl. The confinement of the single spheroid in such a low volume leads to a metabolite concentration change within minutes, resulting in meaningful drug screening results after several hours. Such a non-invasive and label-free approach facilitates an accurate and simple evaluation of metabolic activity during exposure to stimuli and medication, as exemplified on basis of a metabolism-altering drug. This unique combination of precise micromanipulation of individual cancer spheroids and oxygen monitoring within their microenvironment offers the possibility of fully automated high-throughput evaluation of drug screenings as a perspective with regard to, for example, personalized chemotherapy.

3 Methods

3.1 Sensor platform fabrication

Fabrication of the measurement platform started with the processing of the sensor glass chips on a 500 μm thick 4 inch Pyrex borosilicate glass wafer. The wafer was first coated with 500 nm silicon nitride by plasma enhanced physical vapour deposition (PECVD). On top of this insulating layer, a 1.4 μm thick film of the image reversal resist AZ 5214E (Clariant, Switzerland) was spin-coated and patterned through a chromium mask by UV light exposure using the mask aligner MA6B (Süss MicroTec, Germany). 50 nm titanium, 100 nm platinum, and 20 nm titanium were subsequently evaporated and structured in a lift-off process, whereby the titanium layers promoted adhesion of the electrode material platinum. In a second PECVD step, the whole wafer surface was covered with an insulation stack of 800 nm silicon nitride and 200 nm silicon oxide. The insulation was partly opened by reactive ion etching (RIE) to uncover the electrodes and contact pads using a previously patterned mask of the positive resist AZ 1518 (Clariant, Switzerland).

Electrode rims and the walls of the microelectrode wells (Fig. 1b and c) were formed by patterning the permanent epoxy resist SU-8 3000 (Kayaku Advanced Materials, USA) in a two-mask photolithography process. Rim structures around reference, counter, and working electrodes were created by a first 40 μm thick layer of SU-8 3025 through spin-coating, soft-baking, exposure to 360 mJ cm^{-2} UV light and a post-exposure baking step. Subsequently, three consecutive layers of SU-8 3050, each 80 μm thick, were spin-coated. Each layer was soft-baked for 5 min at 65 $^{\circ}\text{C}$ and 25 min at 95 $^{\circ}\text{C}$. In all baking steps, temperature was continuously increased and decreased at 2 $^{\circ}\text{C min}^{-1}$ to minimize delamination of the resist caused by thermal stress. The final 280 μm thick SU-8 layer stack was exposed to 1000 mJ cm^{-2} UV light through an additional chromium mask and post-exposure baked at 65 $^{\circ}\text{C}$ for 5 h to pattern the circular microelectrode wells. Structures were developed in 1-methoxy-2-propanol acetate (Sigma-Aldrich, USA) for 75 min and hard-baked for 3 h at 150 $^{\circ}\text{C}$.

For silver/silver chloride reference electrode fabrication, a 10 μm thick silver layer was deposited by electroplating onto the bare platinum at -16 mA cm^{-2} for 10 min in Arguna S solution (Umicore Galvanotechnik, Germany) and partly converted to silver chloride in 0.1 M KCl solution at 1.6 mA cm^{-2} for 20 min. After wafer-dicing, 21 chips per wafer were obtained and flip-chip bonded onto a custom-made printed circuit board (PCB) with the electrically conductive adhesive Polytec EC 242 (Polytec PT, Germany) and cured at 100 $^{\circ}\text{C}$ for 20 min to electrically connect the electrodes *via* a plug-in connector with the potentiostat. The glass chip was additionally bonded to the PCB by underfilling the biocompatible epoxy-based adhesive Epo-Tek 302-3M (Epoxy Technology, USA) with subsequent curing at room temperature for 24 h in order to seal the electrical connections against cell culture medium.

Reference and working electrodes were coated with a hydrogel membrane composed of pHEMA by manual dispensing of approximately 2 nl into the electrode rims under a stereomicroscope and subsequent curing under UV light. A detailed description of the hydrogel precursor composition can be found elsewhere.¹⁹ A volume of 20 nl of the same hydrogel was dispensed into the cavity between electrode rim and the wall of the microelectrode well (Fig. 1c) and was subsequently UV-cured. Thus, the entire bottom of the microelectrode well, including the oxygen sensor, was covered with a hydrogel membrane on which the spheroid is placed before measurement.

3.2 Cell culture and spheroid formation

MCF-7 human breast cancer cells (cell line obtained from BIOSS Centre for Biological Signalling Studies, Freiburg, Germany) were cultured in Dulbecco's modified Eagle medium (DMEM), high glucose, GlutaMAX Supplement, pyruvate (Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific, USA) and 1% penicillin/streptomycin (Thermo Fisher Scientific,



USA). Harvested cells were resuspended in 3D Tumorsphere Medium XF (PromoCell, Germany), also supplemented with 10% FBS and 1% penicillin/streptomycin, with a concentration of 3.2×10^4 cells per ml, unless stated otherwise.

Cancer cell spheroids were generated *via* hanging-drop method, which is based on the deposition of cell suspension drops by a non-contact dispenser on a target plate. The plate with arrays of drops is rotated 180 degrees and incubated at 37 °C, 95% air humidity and 5% CO₂. Due to gravitational forces, cells accumulate in the lowest point of the drops and form dense 3D cell aggregates due to cell–cell contacts. For this study, an automated non-contact liquid dispenser (I.DOT, DISPENDIX, Germany) was used to produce arrays of 2 µl drops. In brief, cell suspension was filled into the source wells of a dispensing plate (S.100 S, DISPENDIX, Germany). Each source well is equipped with a nozzle at the bottom. The desired drop volume of cell suspension was then dispensed by positive pressure in a 384 micro well plate format array into the lid of a one-well plate (Kisker Biotech, Germany). The lid was then placed on top of the bottom part, which was filled with phosphate buffered saline (PBS) to prevent evaporation of the drops. The plates with the hanging drop arrays remained in the incubator for four days. After this time, spheroids had formed with a diameter of $199 \mu\text{m} \pm 46 \mu\text{m}$ and were harvested by rinsing the plate lid with PBS. Spheroids were collected in a 15 ml tube and centrifuged at 200 g for 5 min. The supernatant was carefully removed, and the spheroids were resuspended in Tumorsphere Medium at a concentration of 1000 spheroids per ml.

Cell viability of the spheroids was determined with a Live/Dead assay following the manufacturer's protocol (LIVE/DEAD™ Viability/Cytotoxicity Kit, for mammalian cells, Thermo Fisher, USA). Briefly summarized, the spheroids were incubated for 30 minutes at room temperature in a 2 µM calcein-AM and 6 µM ethidium homodimer-1 PBS solution. Fluorescent images were acquired with excitation wavelengths of 470 nm and 555 nm with an Observer Z1 microscope (Carl Zeiss, Germany). A 2D cross-sectional image of each spheroid was recorded from three independently conducted examinations. The green color channel showed the calcein-AM signal of living cells and the red color channel showed the fluorescent signal of dead cells due to ethidium homodimer-1 staining of ruptured cell membranes. Viability was calculated as the ratio of the number of living cells and the number of total counted cells per spheroid.

3.3 Bioprinting of single spheroids into microelectrode wells

Single spheroid printing into the microelectrode wells was achieved with an in-house built platform for automated single spheroid deposition which is schematically shown in Fig. 1a and b. The method was based on the concept by Gutzweiler and Kartmann *et al.*¹ A 15 ml tube containing the spheroid suspension was placed into the platform and a thin

polyimide capillary with an inner diameter of 250 µm (Zeus Industrial Products, USA) was inserted into the reservoir with one end and clamped into a non-contact nano-droplet dispenser (PipeJet® nanodispenser, Biofluidix, Germany) with the other end. The periodical movement of the PipeJet's piezo stack actuator caused a squeezing of the tube, which resulted in drops being dispensed. Capillary forces refilled the tube with spheroid suspension from the reservoir after every droplet ejection. A uniform distribution of spheroids in the reservoir and the associated continuous transport of spheroids to the dispenser was maintained by gently pumping the reservoir volume up and down every 5 s at 0.5 ml s⁻¹ using a syringe pump.

The volume of the dispensed droplets was determined *via* computer-based image processing.^{43,44} For this purpose, images of free-flying droplets were acquired with a CMOS camera (nozzle camera, IDS UI-3280CP-M-GL R2, IDS Imaging Development Systems, Germany). Background subtraction of these images was performed, and the drop contour was determined. Then, each pixel row of the drop was treated as a cylinder and the volume of each cylinder stack was summed to estimate the total volume of the droplet.

A motorized xy-stage (Motorized XY aperture stage, 100 mm × 120 mm travel, Zaber Technologies, Canada), on which the target substrate was loaded, controlled the impact position of the droplet. The center coordinates of the impact position were determined by detecting a test drop with a CMOS camera (print position camera, U3-3890CP-M-GL Rev.2, IDS Imaging Development Systems, Germany) and computer-based image processing. For the subsequent spheroid deposition, these coordinates were used as reference printing position.

To enable single spheroid printing, the nozzle region close to the orifice of the capillary protruding the PipeJet was illuminated with a strip LED and observed with the nozzle camera. As soon as a single spheroid was detected in the nozzle region and was to be ejected with the next drop, the motorized xy-stage moved to the microelectrode well at the previously determined reference printing position. The successful drop placement in the well was verified with the print position camera. Two additional drops without spheroids were added to entirely fill the volume of the wells.

3.4 Electrochemical oxygen measurements

The multi-channel potentiostat MultiPalmSens4 (Palmsens, The Netherlands) was used for electrochemical measurements in all experiments and electrically connected to the respective working electrodes, on-chip reference, and counter electrode for simultaneous read-out of multiple sensor electrodes. Before oxygen measurements, which were performed at 37 °C, all sensor electrodes were electrochemically cleaned by performing 100 anodic/cathodic potential cycles at 0.7 V_{Ag/AgCl} and -0.4 V_{Ag/AgCl}, respectively. A combined chronoamperometric/active potentiometric protocol was used to measure the dissolved oxygen





Fig. 2 Accuracy and precision of the impact position regarding single spheroid deposition. (a) Impact position of individually printed drops ($n_{w/o}$ spheroid = 30, n_{with} spheroid = 23) in relation to an initially determined reference printing position (red cross). The mean impact position is displayed by the black cross. The insets show exemplary drops of pure PBS or of PBS containing a spheroid positioned on the NBS 1952 resolution test target slide (crosshair of the slide has a length and width of 610 μm). For clarity, the largest mean diameter of a free-flying droplet just above the sensor well is shown in blue and the size of the sensor well is shown in grey. (b) Side view of a PBS drop ejected from the nozzle and falling into the sensor well. (c) Exemplary image of a spheroid successfully deposited into a sensor well.

successful, highly precise deposition of single spheroids into sensor wells could be achieved and is exemplarily shown in Fig. 2c.

4.2 Automated single spheroid deposition

To automatically deposit single spheroids into the microelectrode wells, we used an in-house developed spheroid-printing algorithm based on Gutzweiler, *et al.*¹ The nozzle region close to the orifice of the capillary where the droplets were ejected was optically monitored with the nozzle camera system. Passing spheroids were detected and tracked. The algorithm was able to predict how many spheroids would be contained in the next ejected droplet to make a decision on where to deposit it. Dispensed droplets can be categorized into single-spheroid droplets (SSD) containing exactly one spheroid, multi-spheroid droplets (MSD) containing more than one spheroid and zero-spheroid droplets (ZSD) containing no spheroids.

In order to quantify the single-spheroid printing rate (SSPR), the system was set to eject droplets into 30 different wells of a 96 micro well plate until a droplet with at least one spheroid was dispensed. The experiment was repeated three times. Afterwards, the number of spheroids in each well was counted with a 4 \times microscope. The SSPR was calculated according to:

$$\text{SSPR} = \frac{f}{\sum_{i=1}^n n_{iD}} \cdot n_{\text{SSD}}, \quad (1)$$

where $f = 5.78 \text{ Hz} \pm 0.26 \text{ Hz}$ was the droplet dispensing frequency of the system, n_{iD} was the total number of droplets which were dispensed into each well i , and n_{SSD} was the number of wells with exactly one spheroid. Furthermore, by dividing the number of wells with exactly one spheroid by the number of all filled wells, it was possible to determine the portion of single-spheroid droplets in relation to all droplets containing at least one spheroid. The results for three different spheroid concentrations in the reservoir are summarized in Table 1. For all wells, the minimum number of spheroids per well was one, and the maximum was three.

Next, the printing algorithm accuracy (PAA) was analysed. The PAA describes the accuracy of the software algorithm in determining the number of spheroids ejected with the last drop. Accurately detecting which spheroids were ejected depends on both the spheroid detection in the capillary and the tracking algorithm. In order to assess the PAA, the spheroid counts per well extracted from the software were compared with the counted spheroids under the microscope. The PAA for different spheroid concentrations in the reservoir can be found in Table 1 and was determined as:

Table 1 Analysis for different reservoir concentrations of the single spheroid printing rate (SSPR), the probability of single-spheroid droplets (SSD) in relation to multi-spheroid droplets (MSD) and the printing algorithm accuracy (PAA). n_{SSD} is the observed number of droplets containing exactly one spheroid, and n_{MSD} is the observed number of droplets containing more than one spheroid within one run

Reservoir concentration [spheroids per ml]	SSPR [min^{-1}]	$\frac{n_{\text{SSD}}}{n_{\text{SSD}} + n_{\text{MSD}}} [\%]$	PAA [%]
300	1.9 ± 0.6	88.9 ± 1.9	93.3 ± 3.3
1000	6.1 ± 1.5	88.9 ± 3.8	93.3 ± 3.3
2000	15.2 ± 6.9	81.1 ± 3.8	86.7 ± 8.8



$$\text{PAA} = \frac{\text{number of wells with correctly counted spheroid number}}{\text{total number of filled wells}} \quad (2)$$

The data in Table 1 shows that with an increased spheroid concentration in the reservoir, the single spheroid printing rate also increased, as expected. Likewise, however, the probability of MSDs which were not suitable for single spheroid printing increased. In addition, the PAA deteriorated with a higher spheroid concentration due to the increased number of spheroids passing the nozzle at the same time. Thus, it was more complex to distinguish individual spheroids and to precisely determine the number of spheroids that were ejected with the last droplet.

A concentration of 1000 spheroids per ml has proven to be an advantageous spheroid concentration in the reservoir. The high accuracy with which the spheroids were detected and automatically deposited, as well as the high probability that the drops contained no more than one spheroid, guaranteed a low-loss and reliable single spheroid deposition process with sufficient efficiency. For the oxygen measurement, only SSDs were deposited into the microelectrode wells. Empty droplets or droplets containing more than one spheroid were printed into a collection container.

4.3 Spheroid vitality and integrity after deposition

During the bioprinting process, the spheroids were subject to different possible stress factors, namely gentle mixing, aspiration, and transport through a thin capillary, ejection, and impact on a target. To rule out that the spheroid processing had negative effects on the sample and therefore producing misleading sensor signals, the cell viability and the integrity of the cell aggregates were examined.

Cell viability of 58 processed spheroids was analyzed and compared to 50 harvested, but unprocessed spheroids as control (Fig. 3a and b) in three independent samples. In total, the viability analysis was carried out with 1478 cells of the control sample and 1773 cells of the processed sample.

Fig. 3b shows that the mean viability of processed spheroids of $93.1\% \pm 5.8\%$ did not differ significantly from the viability of the control sample of $93.9\% \pm 5.0\%$. This behavior was in accordance with the estimated shear stress due to sample mixing and bioprinting, which did not exceed 25 mPa and 60 mPa, respectively, and was therefore below or in the order of physiological relevant shear stress values.⁴⁶

In addition, the integrity was examined by determining the spheroid area before and after the bioprinting process. The contours of 50 spheroids each of the control and the processed sample were identified and the resulting area was normalized by the median of the control (Fig. 3c). The mean diameter of the unprocessed spheroids of $199 \mu\text{m} \pm 46 \mu\text{m}$ did not differ significantly from the mean diameter of the bioprinted spheroids of $200 \mu\text{m} \pm 26 \mu\text{m}$ indicating that spheroids remained intact after deposition.

4.4 Oxygen sensor characteristics

The dissolved oxygen concentration was measured using platinum-based amperometric microelectrodes at the microwells' bottom. Highly stable and reproducible sensor performance was achieved by applying an advanced chronoamperometric protocol, in which the platinum surface is first electrochemically cleaned by an anodic and cathodic potential pulse prior the actual oxygen measurement by its reduction at $-0.3 \text{ V}_{\text{Ag}/\text{AgCl}}$. Transient current responses are shown for atmospheric and anoxic conditions in Fig. 4a. This method allows the oxygen reduction reaction to take place on a renewed platinum surface each time the measurement is performed, eliminating electrode fouling even in serum-containing electrolytes. Additionally, an electrode covering PHEMA-based hydrogel membrane was used to improve sensor long-term stability by preventing the settlement of blocking substances and a direct contact between spheroid and electrode surface.

Sensor calibration (Fig. 4b and c) was performed in the used cell culture medium and PBS with a high precision (relative error $<2.5\%$ across the whole measurement range) and a limit of detection of below $1 \mu\text{M}$, based on three times



Fig. 3 Influence of the bioprinting process on spheroid viability. (a) Representative live/dead staining of cells in a spheroid. Cyan-colored cells were living, and red-colored cells were dead. (b) Cell viability of unprocessed control spheroids and processed and bioprinted spheroids ($N_{\text{Control}} = 3$, $n_{\text{Control}} = 50$; $N_{\text{Printed}} = 3$, $n_{\text{Printed}} = 58$). (c) Spheroid area of unprocessed and processed spheroids normalized to the median of the unprocessed control sample ($n_{\text{Control}} = n_{\text{Printed}} = 50$). P values ≥ 0.05 were considered not being significant (n.s.).





Fig. 4 Oxygen sensor characteristics. (a) Transient current responses at an acquisition rate of 10 Hz during the execution of the chronoamperometric protocol used for oxygen measurement within anoxic and atmospheric oxygen concentrations in PBS. (b) Oxygen sensor signal during six calibration cycles in PBS, in which the dissolved oxygen concentration was varied by means of a gas-mixing station. (c) Oxygen calibration in cell culture medium and PBS, showing no significant difference in sensitivity. Error bars are s.d. (d) Comparison of the oxygen concentration within an open and closed microwell. While atmospheric conditions in an open microwell resulted in a constant sensor current, the current in a closed microwell decreased rapidly due to the exclusion of additional oxygen influx.

the standard deviation of the blank signal. At $-0.34 \mu\text{A cm}^{-2} \mu\text{M}^{-1}$, the sensor sensitivity was only slightly lower in cell culture medium than in PBS ($-0.37 \mu\text{A cm}^{-2} \mu\text{M}^{-1}$). Moreover, we demonstrated in a prior work,²⁴ that such oxygen sensors can be operated in cell culture medium over a period of one week without a measurable change in sensitivity. The sensor method allows a one-point calibration, as the sensor current is nearly zero under conditions without oxygen and increases linearly until an oxygen concentration at atmospheric conditions, eliminating time-consuming calibration measurements at various concentrations.

Since oxygen is consumed by the sensor electrodes and is only available to a limited extent within the closed low-volume microelectrode wells, minimizing oxygen uptake by the electrodes was intended. Therefore, compared to the previously reported chronoamperometric oxygen measurement protocols,^{9,13,18} pulse durations were reduced by 50% to a total sensor on-time of 4 s. In addition, the diffusion limiting pHEMA membrane lowered the oxygen flux to the electrode during sensor on-times, further limiting consumption.

Oxygen dissolves at the electrolyte surface and spreads within the liquid by diffusion and convection. In an

uncovered microelectrode well, oxygen from the medium could reach the microelectrode well unhindered, resulting in a high steady-state current corresponding to an atmospheric oxygen concentration, as shown in Fig. 4d. Under these conditions, the sensor currents in PBS and cell culture medium were nearly the same, indicating that the same amount of oxygen dissolves in both liquids and consequently implying the same strength of the salting out effect. Once the volume in the well was sealed by a glass cover, additional influx of oxygen from the microelectrode wells' electrolyte-environment was drastically reduced. Thus, due to consumption by the electrode, the oxygen concentration began to decrease nearly linearly during the first 15 min. The concentration did not drop continuously to zero, as a small amount of oxygen still reached the inside due to a remaining gap between microelectrode well wall and cover. Instead, a concentration equilibrium established at approximately $50 \mu\text{M}$. Since an ion flux in the electrolyte between working and counter electrode is required during the electrochemical measurement, a complete isolation of the inner volume from the electrolyte environment is impossible. Additionally, this would increase the resistance between the working and reference electrode, resulting in an undesired high potential





Fig. 5 Oxygen monitoring and respiration of single MCF-7 spheroids. (a) Comparison of sensor currents during amperometric oxygen measurements with an untreated spheroid and after exposure to 100 μM antimycin A. In addition, the oxygen concentration course of a blank measurement without incorporated spheroid is shown. (b) Transient amperometric oxygen measurement in a typical long-term drug response experiment, in which the microwell is periodically covered with a glass slide. (c) Potentiometric sensor signals during OCP phases, showing a high stability of electrode potentials and a decreased equilibrium potential at low dissolved oxygen concentrations. (d) Oxygen consumption rates of three representative MCF-7 spheroids before and after the exposure to 100 μM antimycin A. The blank signal was subtracted for data evaluation.

drop. Therefore, a trade-off between gas tightness and ionic conductivity has to be found. However, since the measurements in the following did not exceed 10 minutes under closed conditions, and a nearly linear decrease in oxygen concentration was observed during this duration (Fig. 4d), it can be assumed that the amount of additional inflowing oxygen molecules is negligible for monitoring the oxygen uptake of single spheroids.

4.5 Monitoring the oxygen microenvironment of single spheroids

Fig. 5a compares the course of the oxygen concentration in a microelectrode well with an incorporated spheroid to the same microelectrode well without spheroid, before and after the addition of the aerobic metabolism-suppressing drug antimycin A. Oxygen concentration was measured continuously, once per minute. While the microelectrode well was open, the sensor currents showed a constant value that corresponded to the oxygen concentration at air saturation. In the case of the untreated spheroid, the oxygen concentration during open conditions was slightly below that atmospheric steady-state value of the blank, due to additional oxygen consumption of the spheroid. By covering the microelectrode well with a glass slide, the inner volume was

isolated from its surrounding cell culture medium. This limited the amount of oxygen molecules in the well so that almost no additional oxygen could enter from the environment and solely the sensor electrode and the spheroid were responsible for a change in oxygen concentration. Due to the high cellular oxygen consumption of the untreated spheroid, the concentration decreased linearly and reached anoxic conditions after 8 minutes. After addition of 100 μM antimycin A, which stopped the aerobic metabolism of the spheroid by interrupting the mitochondrial respiratory chain,⁴⁷ the decrease in oxygen was significantly reduced (by approx. 95%) and close to the course without spheroid. After 10 minutes, the glass slide was removed, resulting in an increase in sensor current as fresh cell culture medium could enter its inner volume and re-establish atmospheric conditions.

By periodically covering and opening the microelectrode wells every 10 minutes, a long-term measurement was recorded (Fig. 5b). The oxygen concentration temporarily exceeded the atmospheric baseline upon addition of the drug-containing medium, due to its lower temperature (room temperature vs. 37 °C) and consequently higher solubility of oxygen. Oxygen consumption rates could be estimated from the slopes of the decreasing sensor signals during closed conditions and are shown in Fig. 5d for three representative



MCF-7 spheroids of approximately the same size ($153 \mu\text{m} \pm 8 \mu\text{m}$, $n = 3$) before and after treatment, respectively. Subtraction of the blank signal eliminated the electrodes' influence on the oxygen concentration. Measured oxygen consumption rates for untreated MCF-7 spheroids at 450–850 fmol min^{-1} (Fig. 5d) were similar to those of previous studies,^{31,34,48–50} and were close to zero after antimycin A treatment. For each individual untreated spheroid, respiration rates could be measured with a high precision of 12% ($n = 3 \times 5$) relative error. Since the deviation of one spheroid's average respiration rate was greater than the scatter within the measurements, we attribute this result to an actual increase in cellular respiration.

Besides oxygen reduction currents measured with the chronoamperometric method, electrode potentials were recorded throughout the open-circuit phases by active potentiometry. Fig. 5c shows the electrode potentials evaluated 20 s after the final cathodic pulse. At normoxic oxygen concentrations, the electrode potentials remained at a constant value, much more positive than the previously applied potential of $-0.3 V_{\text{Ag}/\text{AgCl}}$. That occurs because, in the presence of dissolved oxygen, the oxide-free platinum surface generated at $-0.3 V_{\text{Ag}/\text{AgCl}}$ oxidizes to platinum oxide with the molecular oxygen reduction acting as the counter process in a local element at the working electrode. That leads to a higher pseudo-equilibrium potential after 20 s of open circuit.⁵¹ In the closed microelectrode well with untreated spheroids, the potential became more negative with decreasing oxygen concentration, because Pt oxidation happened to a lesser extent due to the lack of dissolved oxygen.

First, the active potentiometric measurements qualitatively confirmed the amperometric measurements using a different sensor principle. Second, due to the logarithmic transfer function of the potentiometric measurement, it has a higher sensitivity at low concentrations and therefore can still measure changes at the anoxic level, where the amperometric signal already is nearly constant. Third, the absence of a significant baseline potential drift of the electrodes during the measurements underlines the stability of the electrochemical cell and proper connection to the reference electrode when closing and opening the microelectrode well.

Overall, the electrochemical measurements demonstrated that electrochemical sensors can reproducibly and precisely measure dissolved oxygen concentrations online in microelectrode wells and enable determination of single tumour spheroid respiration rates within hours.

5 Conclusions

For the first time, we have demonstrated the combination of advanced DoD bioprinting techniques with chip-based microsensors, in order to print tumour spheroids directly into microsensor wells and measure single spheroid respiration rates. Using bioprinting to deposit 3D cell culture models into lab-on-a-chip sensor systems is a

valuable step towards the much-needed facilitation, scale-up and parallelization in cell culture monitoring. Such efforts are desirable to reduce overall workload and increase the standardization and reliability of experiments in order to ultimately increase the adoption rate of microsystems and microsensors into higher throughput cell biology lab routines. Bioprinting offers a high degree of automation, ranging from spheroid formation, over spheroid printing to other liquid handling procedures that may be required, *e.g.* in drug screening or dose response measurements and can be flexibly adapted to the application. We have successfully demonstrated that bioprinting can deliver 3D cell culture models to microsensor electrodes with high spatial accuracy in the micrometre-range, with reproducible droplet volumes and a high cell viability not affected by the printing process. Off-chip spheroid generation and subsequent printing with direct measurement streamlines the workflow and allows fast access to the metabolism of fully developed spheroids. The automation solution of the bioprinting approach is compatible with a variety of different cell models and promises a potentially facile approach for co-integration of different cell types, as desired *e.g.* in complex tumour models or organs-on-chip. It also eliminates microfluidic structures and handling steps for spheroid deposition reducing the risk of cross-contamination by exchanging contaminated parts after every use. It meets the challenge of bringing spheroids reproducibly close to microsensors for successful low-volume, short distance measurements. The microstructures forming the electrode wells and the hydrogel coating further support the positioning of spheroids. Electrochemical oxygen microsensors allow the precise and reproducible monitoring of breast cancer spheroid respiration rates. Metabolic rates can be determined minutes after printing, and drug screening experiments can be accomplished within hours. In the future, the electrochemical sensor principle allows an easy co-integration with other sensors, such as enzymatic biosensors, *e.g.* for glucose and lactate, as well as reactive oxygen or nitrogen species for which microfluidic principles are less suitable due to the short diffusion length of the substances. Overall, the involved steps have a high potential for upscaling. The combination of such fully automated and highly capable spheroid manipulation and microsensor-based evaluation on a molecular level is a further milestone towards a more efficient 3D cell culture monitoring. Its relevance ranges from fundamental metabolic research, standardization of cell culture experiments, and toxicological studies to personalized medicine.

Author contributions

Conceptualization: JD, VZ, JK, SK, AW; investigation: JD, VZ; software: DF; writing – original draft preparation: JD, VZ; writing – review & editing: JK, RZ, GU, SK, AW; visualization: JD, VZ, AW; supervision: JK, RZ, GU, SK, AW.



Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We thank Tobias Lange for his assistance with cell culture. Partial funding by the German Federal Ministry of Education and Research, grant number 161L0235B, is gratefully acknowledged.

References

- L. Gutzweiler, S. Kartmann, K. Troendle, L. Benning, G. Finkenzeller, R. Zengerle, P. Koltay, G. B. Stark and S. Zimmermann, *Biofabrication*, 2017, **9**, 025027.
- V. Brancato, J. M. Oliveira, V. M. Correlo, R. L. Reis and S. C. Kundu, *Biomaterials*, 2020, **232**, 119744.
- B. Pinto, A. C. Henriques, P. M. A. Silva and H. Bousbaa, *Pharmaceutics*, 2020, **12**, 1–38.
- L. A. Low, C. Mummery, B. R. Berridge, C. P. Austin and D. A. Tagle, *Nat. Rev. Drug Discovery*, 2021, **20**, 345–361.
- K. Moshksayan, N. Kashaninejad, M. E. Warkiani, J. G. Lock, H. Moghadas, B. Firoozabadi, M. S. Saidi and N. T. Nguyen, *Sens. Actuators, B*, 2018, **263**, 151–176.
- J. L. Leight, A. P. Drain and V. M. Weaver, *Annu. Rev. Cancer Biol.*, 2017, **1**, 313–334.
- D. Liu, S. Chen and M. Win Naing, *Biotechnol. Bioeng.*, 2021, **118**, 542–554.
- J. Kieninger, A. Weltin, H. Flamm and G. A. Urban, *Lab Chip*, 2018, **18**, 1274–1291.
- J. Marzioch, J. Kieninger, A. Weltin, H. Flamm, K. Aravindalochanan, J. A. Sandvik, E. O. Pettersen, Q. Peng and G. A. Urban, *Lab Chip*, 2018, **18**, 3353–3360.
- A. Moya, M. Ortega-Ribera, X. Guimerà, E. Sowade, M. Zea, X. Illa, E. Ramon, R. Villa, J. Gracia-Sancho and G. Gabriel, *Lab Chip*, 2018, **18**, 2023–2035.
- E. Tanumihardja, R. H. Slaats, A. D. Van Der Meer, R. Passier, W. Olthuis and A. Van Den Berg, *ACS Sens.*, 2021, **6**, 267–274.
- W. Shang, C. Y. Chen, K. Lo, G. F. Payne and W. E. Bentley, *Sens. Actuators, B*, 2019, **295**, 30–39.
- A. Weltin, K. Slotwinski, J. Kieninger, I. Moser, G. Jobst, M. Wego, R. Ehret and G. A. Urban, *Lab Chip*, 2014, **14**, 138–146.
- P. Wolf, M. Brischwein, R. Kleinhans, F. Demmel, T. Schwarzenberger, C. Pfister and B. Wolf, *Biosens. Bioelectron.*, 2013, **50**, 111–117.
- P. Pellegrini, J. T. Serviss, T. Lundbäck, N. Bancaro, M. Mazurkiewicz, I. Kolosenko, D. Yu, M. Haraldsson, P. D'Arcy, S. Linder and A. De Milito, *Cancer Cell Int.*, 2018, **18**, 1–15.
- H. Azizgolshani, J. R. Coppeta, E. M. Vedula, E. E. Marr, B. P. Cain, R. J. Luu, M. P. Lech, S. H. Kann, T. J. Mulhern, V. Tandon, K. Tan, N. J. Haroutunian, P. Keegan, M. Rogers, A. L. Gard, K. B. Baldwin, J. C. de Souza, B. C. Hoefler, S. S. Bale, L. B. Kratchman, A. Zorn, A. Patterson, E. S. Kim, T. A. Petrie, E. L. Wietzel, C. Williams, B. C. Isenberg and J. L. Charest, *Lab Chip*, 2021, **21**, 1454–1474.
- H. Zirath, M. Rothbauer, S. Spitz, B. Bachmann, C. Jordan, B. Müller, J. Ehgartner, E. Priglinger, S. Mühleder, H. Redl, W. Holnthoner, M. Harasek, T. Mayr and P. Ertl, *Front. Physiol.*, 2018, **9**, 815.
- J. Kieninger, K. Aravindalochanan, J. A. Sandvik, E. O. Pettersen and G. A. Urban, *Cell Proliferation*, 2014, **47**, 180–188.
- J. Kieninger, Y. Tamari, B. Enderle, G. Jobst, J. A. Sandvik, E. O. Pettersen and G. A. Urban, *Biosensors*, 2018, **8**, 44.
- K. Domansky, W. Inman, J. Serdy, A. Dash, M. H. M. Lim and L. G. Griffith, *Lab Chip*, 2010, **10**, 51–58.
- M. A. Ortega, X. Fernández-Garibay, A. G. Castaño, F. De Chiara, A. Hernández-Albors, J. Balaguer-Trias and J. Ramón-Azcón, *Lab Chip*, 2019, **19**, 2568–2580.
- Y. S. Zhang, J. Aleman, S. R. Shin, T. Kilic, D. Kim, S. A. M. Shaegh, S. Massa, R. Riahi, S. Chae, N. Hu, H. Avcı, W. Zhang, A. Silvestri, A. S. Nezhad, A. Manbohi, F. De Ferrari, A. Polini, G. Calzone, N. Shaikh, P. Alerasool, E. Budina, J. Kang, N. Bhise, J. Ribas, A. Pourmand, A. Skardal, T. Shupe, C. E. Bishop, M. R. Dokmeci, A. Atala and A. Khademhosseini, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**, E2293–E2302.
- S. Eggert, M. S. Gutbrod, G. Liebsch, R. Meier, C. Meinert and D. W. Huttmacher, *ACS Sens.*, 2021, **6**, 1248–1260.
- J. Dornhof, J. Kieninger, H. Muralidharan, J. Maurer, G. A. Urban and A. Weltin, *Lab Chip*, 2022, **22**, 225–239.
- P. M. Misun, J. Rothe, Y. R. F. Schmid, A. Hierlemann and O. Frey, *Microsyst. Nanoeng.*, 2016, **2**, 16022.
- N. Rousset, R. L. Sandoval, M. M. Modena, A. Hierlemann and P. M. Misun, *Microsyst. Nanoeng.*, 2022, **8**, 14.
- D. Bavli, S. Prill, E. Ezra, G. Levy, M. Cohen, M. Vinken, J. Vanfleteren, M. Jaeger and Y. Nahmias, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**, E2231–E2240.
- S. Russell, J. Wojtkowiak, A. Neilson and R. J. Gillies, *Sci. Rep.*, 2017, **7**, 1–11.
- K. Ino, M. Şen, H. Shiku and T. Matsue, *Analyst*, 2017, **142**, 4343–4354.
- A. Weltin, S. Hammer, F. Noor, Y. Kaminski, J. Kieninger and G. A. Urban, *Biosens. Bioelectron.*, 2017, **87**, 941–948.
- R. Mukomoto, Y. Nashimoto, T. Terai, T. Imaizumi, K. Hiramoto, K. Ino, R. Yokokawa, T. Miura and H. Shiku, *Analyst*, 2020, **145**, 6342–6348.
- A. Sridhar, H. L. De Boer, A. Van Den Berg and S. Le Gac, *PLoS One*, 2014, **9**, e93618.
- K. Ino, Y. Yamada, Y. Kanno, S. Imai, H. Shiku and T. Matsue, *Sens. Actuators, B*, 2016, **234**, 201–208.
- H. Kurosawa, H. Utsunomiya, N. Shiga, A. Takahashi, M. Ihara, M. Ishibashi, M. Nishimoto, Z. Watanabe, H. Abe, J. Kumagai, Y. Terada, H. Igarashi, T. Takahashi, A. Fukui, R. Suganuma, M. Tachibana and N. Yaegashi, *Hum. Reprod.*, 2016, **31**, 2321–2330.
- Y. Date, S. Takano, H. Shiku, K. Ino, T. Ito-Sasaki, M. Yokoo, H. Abe and T. Matsue, *Biosens. Bioelectron.*, 2011, **30**, 100–106.
- Y. Xiang, K. Miller, J. Guan, W. Kiratitanaporn, M. Tang and S. Chen, *Arch. Toxicol.*, 2022, **96**, 691–710.



- 37 J. Zhang, E. Wehrle, M. Rubert and R. Müller, *Int. J. Mol. Sci.*, 2021, **22**, 3971.
- 38 K. Tröndle, L. Rizzo, R. Pichler, F. Koch, A. Itani, R. Zengerle, S. S. Lienkamp, P. Koltay and S. Zimmermann, *Biofabrication*, 2021, **13**, 035019.
- 39 R. H. Utama, L. Atapattu, A. P. O'Mahony, C. M. Fife, J. Baek, T. Allard, K. J. O'Mahony, J. C. C. Ribeiro, K. Gaus, M. Kavallaris and J. J. Gooding, *iScience*, 2020, **23**, 101621.
- 40 H. Chen, Z. Wu, Z. Gong, Y. Xia, J. Li, L. Du, Y. Zhang, X. Gao, Z. Fan, H. Hu, Q. Qian, Z. Ding and S. Guo, *Adv. Healthcare Mater.*, 2022, **11**, 1–11.
- 41 D. N. Heo, B. Ayan, M. Dey, D. Banerjee, H. Wee, G. S. Lewis and I. T. Ozbolat, *Biofabrication*, 2021, **13**, 015013.
- 42 B. Ayan, D. N. Heo, Z. Zhang, M. Dey, A. Povilianskas, C. Drapaca and I. T. Ozbolat, *Sci. Adv.*, 2020, **6**, 1–17.
- 43 D. Liang, T. G. Muniyogeshbabu, L. Tanguy, A. Ernst, R. Zengerle and P. Koltay, *Proc. 1st Int. Conf. Micro Fluid. Handl. Syst.*, 2012, vol. c, pp. 95–98.
- 44 ISO 23783-2:2022, Automated liquid handling systems — Part 2: Measurement procedures for the determination of volumetric performance, 2022.
- 45 P. Zimmermann, A. Weltin, G. A. Urban and J. Kieninger, *Sensors*, 2018, **18**, 2404.
- 46 U. L. Triantafillu, S. Park, N. L. Klaassen, A. D. Raddatz and Y. Kim, *Int. J. Oncol.*, 2017, **50**, 993–1001.
- 47 S. Tzung, K. M. Kim, G. Basañez, C. D. Giedt, J. Simon, J. Zimmerberg, K. Y. J. Zhang and D. M. Hockenbery, *Nat. Cell Biol.*, 2001, **3**, 183–191.
- 48 Y. Zhou, T. Arai, Y. Horiguchi, K. Ino, T. Matsue and H. Shiku, *Anal. Biochem.*, 2013, **439**, 187–193.
- 49 L. Jiang, A. A. Shestov, P. Swain, C. Yang, S. J. Parker, Q. A. Wang, L. S. Terada, N. D. Adams, M. T. McCabe, B. Pietrak, S. Schmidt, C. M. Metallo, B. P. Dranka, B. Schwartz and R. J. Deberardinis, *Nature*, 2016, **532**, 255–258.
- 50 G. Campioni, V. Pasquale, S. Busti, G. Ducci, E. Sacco and M. Vanoni, *Cell*, 2022, **11**, 1–22.
- 51 A. Weltin and J. Kieninger, *J. Neural Eng.*, 2021, **18**, 052001.

